Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus etanercept cardiovascular outcomes study in rheumatoid arthritis
2010-020065-24Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of tocilizumab and etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Major adverse cardiovascular events composite. Started Apr 2011; status: completed.
02
Drugs
tocilizumabetanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-020065-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020065-24.